Track how many active mutual funds hold pharma CDMO stocks in India. Monthly data shows where institutional conviction across Divi Labs, Laurus Labs, Syngene, Piramal Pharma, Concord Biotech, Gland Pharma, Neuland, Sai Life Sciences and others is rising or falling.
📅 Updated Jul 2026 · Index funds and ETFs excluded
| # | Stock Name | Apr | May % | Jun % | Jul % | Jul 2026 Funds | Overall % | AUM (₹ Cr) |
|---|---|---|---|---|---|---|---|---|
| 1 | Divi's Laboratories LimitedPharmaceuticals & Biotechnology | 148 | +4.1% | +2.6% | -2.5% | 154 | +4.1% | 22,861 |
| 2 | Sai Life Sciences LimitedPharmaceuticals & Biotechnology | 70 | +15.7% | +6.2% | -12.8% | 75 | +7.1% | 6,508 |
| 3 | Anthem Biosciences LimitedPharmaceuticals & Biotechnology | 64 | -3.1% | +17.7% | -4.1% | 70 | +9.4% | 4,203 |
| 4 | Gland Pharma LimitedPharmaceuticals & Biotechnology | 52 | +15.4% | +5% | -7.9% | 58 | +11.5% | 9,291 |
| 5 | Neuland Laboratories LimitedPharmaceuticals & Biotechnology | 52 | +11.5% | -1.7% | -7% | 53 | +1.9% | 3,043 |
| 6 | Laurus Labs LimitedPharmaceuticals & Biotechnology | 42 | +19% | +2% | -5.9% | 48 | +14.3% | 6,207 |
| 7 | Syngene International LimitedHealthcare Services | 50 | -4% | 0% | -8.3% | 44 | -12% | 3,496 |
| 8 | Cohance Lifesciences LimitedPharmaceuticals & Biotechnology | 40 | -7.5% | 0% | 0% | 37 | -7.5% | 2,031 |
| 9 | Piramal Pharma LimitedPharmaceuticals & Biotechnology | 32 | +6.3% | -2.9% | +6.1% | 35 | +9.4% | 3,244 |
| 10 | Onesource Specialty Pharma LimitedPharmaceuticals & Biotechnology | 32 | +3.1% | -3% | 0% | 32 | 0% | 2,322 |
| 11 | Rubicon Research LimitedPharmaceuticals & Biotechnology | 17 | +29.4% | 0% | +4.5% | 23 | +35.3% | 1,684 |
| 12 | Jubilant Pharmova LimitedPharmaceuticals & Biotechnology | 19 | 0% | 0% | -10.5% | 17 | -10.5% | 1,262 |
| 13 | Concord Biotech LimitedPharmaceuticals & Biotechnology | 11 | +9.1% | +16.7% | 0% | 14 | +27.3% | 598 |
| 14 | Shilpa Medicare LtdPharmaceuticals & Biotechnology | 13 | 0% | -7.7% | 0% | 12 | -7.7% | 432 |
| 15 | Akums Drugs and Pharmaceuticals LimitedPharmaceuticals & Biotechnology | 9 | 0% | 0% | -11.1% | 8 | -11.1% | 726 |
| 16 | Blue Jet Healthcare LtdPharmaceuticals & Biotechnology | 2 | 0% | +100% | +100% | 8 | +300% | 133 |
| 17 | Innova Captab LimitedPharmaceuticals & Biotechnology | 9 | 0% | +11.1% | -20% | 8 | -11.1% | 467 |
| 18 | EQ - WINDLAS BIOTEC LTDPharmaceuticals & Biotechnology | 3 | 0% | 0% | 0% | 3 | 0% | 44 |
| 19 | Aarti Drugs LtdPharmaceuticals & Biotechnology | 3 | -33.3% | 0% | 0% | 2 | -33.3% | 306 |
| 20 | Dishman Carbogen Amcis LimitedPharmaceuticals & Biotechnology | 1 | 0% | 0% | 0% | 1 | 0% | 41 |
| 21 | Hikal LimitedPharmaceuticals & Biotechnology | 1 | 0% | 0% | 0% | 1 | 0% | 73 |
| 22 | IOL Chemicals and Pharmaceuticals LimitedPharmaceuticals & Biotechnology | — | — | — | — | 1 | — | 7 |
| 23 | Suven Life Sciences LimitedHealthcare Services | 1 | 0% | -100% | — | — | -100% | — |
Pharma CDMO stocks include companies that manufacture active pharmaceutical ingredients and drug formulations under contract for innovator and generic drug companies globally. India has emerged as a leading CDMO destination due to its chemistry expertise, cost advantages, and regulatory track record. Key names tracked by funds include Divi Laboratories in APIs and custom synthesis, Laurus Labs in ARV and CDMO, Syngene International in biologics and discovery research, Piramal Pharma and Gland Pharma in injectable CDMO, Concord Biotech in fermentation-based APIs, Neuland and Dishman Carbogen in complex APIs, and Sai Life Sciences and Blue Jet Healthcare in high-potency and contrast media chemistry.
Rising fund counts over four months signal growing institutional conviction in the pharma CDMO theme. Cross-reference individual fund portfolios on our top stocks page or explore full holdings via the funds directory.
Global pharmaceutical companies are actively diversifying their API and formulation supply chains away from China and India CDMO companies are the primary beneficiaries. The China plus one strategy has accelerated post-COVID as supply chain resilience became a boardroom priority. Indian CDMOs are also winning new biologics and high-potency molecule contracts that require sophisticated chemistry capabilities. Regulatory approvals from USFDA, EMA and other agencies give Indian CDMOs access to the highest-value global contracts. Fund managers view pharma CDMO as a high-quality export theme with multi-year revenue visibility.
For context on SEBI disclosure requirements, refer to AMFI India. For regulatory guidelines, visit SEBI India. Explore broader holding trends using our market cap categories page.
The AUM column shows the total market value of holdings in that stock across all active equity mutual funds in the latest month, expressed in crores of rupees. A high AUM alongside a rising fund count signals strong and growing conviction, while a falling fund count with still-high AUM may indicate remaining funds are holding larger positions even as others exit. This data is updated automatically each month as new portfolio disclosures are uploaded.
To explore individual fund portfolios and see which specific funds hold each pharma CDMO stock, visit the funds directory or click any stock name in the table above. Use the SIP calculator to plan investments in funds with high pharma sector exposure. For a broader market view, see our AAUM data page.